Close Menu

NEW YORK (GenomeWeb) – Kevin Ness has a vision: the CEO of gene editing company Inscripta wants to make CRISPR technology as ubiquitous as DNA sequencing. He believes there's just one problem — too many researchers can't get their hands on the basic tools they need.

"All the CRISPR research that could be done isn't being done because people don't have access to the enzymes, and that's a problem that we're looking to solve — getting complete, unrestricted, open access to these enzymes immediately," he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.